|5.37 0.47 (9.59%)||12-01 16:00|
|Targets||6-month :||6.75||1-year :||7.88|
|Resists||First :||5.78||Second :||6.75|
|Supports||First :||4.5||Second :||3.72|
|MAs||MA(5) :||4.8||MA(20) :||4.56|
|MA(100) :||5.59||MA(250) :||10.68|
|MACD||MACD :||-0.1||Signal :||-0.2|
|%K %D||K(14,3) :||88.7||D(3) :||75.7|
|52-week||High :||20||Low :||3.72|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PEPG ] has closed Bollinger Bands are 25.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||5.49 - 5.51||5.51 - 5.53|
|Low:||4.78 - 4.8||4.8 - 4.83|
|Close:||5.33 - 5.37||5.37 - 5.41|
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||24 (M)|
|Shares Float||8 (M)|
|Held by Insiders||0 (%)|
|Held by Institutions||97.7 (%)|
|Shares Short||297 (K)|
|Shares Short P.Month||248 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||5.28|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-27.3 %|
|Return on Equity (ttm)||-46.5 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-63 (M)|
|Levered Free Cash Flow||-39 (M)|
|Price to Book value||1.01|
|Price to Sales||0|
|Price to Cash Flow||-2.04|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|